Abstract
Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression. However, most investigations have mainly focused on the genetic alterations of nuclear DNA. The potential role of mitochondrial DNA (mtDNA) mutations in thyroid tumorigenesis is not well defined. In the present study, we investigated the frequency of mtDNA mutations in 24 thyroid tumor specimens (19 primary papillary thyroid carcinomas (PTC), one follicular thyroid carcinoma, and four multinodular hyperplasias) and four thyroid cancer cell lines by sequencing the entire coding regions of mitochondrial genome. Among the 19 PTC samples tested, seven (36.8%) had somatic mutations. Somatic mtDNA mutations were also detected in one of four multinodular hyperplasias examined. All the thyroid tumor cell lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants. Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines revealed a severe defect in mitochondrial complex I activity. The majority of the mutations was involved in genes located in the complex I of the mitochondrial genome. The mutations were either A → G or C → T transitions, often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. These data suggest that mtDNA mutations may play an important role in the thyroid tumorigenesis. Given that mtDNA mutation is present in the benign multinodular hyperplasia, it might be involved in the early stage of tumor development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abu-Amero K, Zou M and Shi Y . (2004). Clinical Genetics, 66, 569–570.
Beckman KB and Ames BN . (1997). J. Biol. Chem., 272, 19633–19636.
Bosley TM, Abu-Amero KK and Ozand PT . (2004). Neurology, 63, 1305–1308.
Cadet J, Berger M, Douki T and Ravanat JL . (1997). Rev. Physiol. Biochem. Pharmacol., 131, 1–87.
Chagnon P, Gee M, Filion M, Robitaille Y, Belouchi M and Gauvreau D . (1999). Am. J. Med. Genet., 85, 20–30.
Corona P, Antozzi C, Carrara F, D'Incerti L, Lamantea E, Tiranti V and Zeviani M . (2001). Ann. Neurol., 49, 106–110.
Croteau DL and Bohr VA . (1997). J. Biol. Chem., 272, 25409–25412.
Eng C, Kiuru M, Fernandez MJ and Aaltonen LA . (2003). Nat. Rev. Cancer, 3, 193–202.
Farid NR, Shi Y and Zou M . (1994). Endocr. Rev., 15, 202–232.
Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J and Sidransky D . (2000). Science, 287, 2017–2019.
Hartman P, Ponder R, Lo HH and Ishii N . (2004). Mech. Ageing Dev., 125, 417–420.
Jeronimo C, Nomoto S, Caballero OL, Usadel H, Henrique R, Varzim G, Oliveira J, Lopes C, Fliss MS and Sidransky D . (2001). Oncogene, 20, 5195–5198.
Jones JB, Song JJ, Hempen PM, Parmigiani G, Hruban RH and Kern SE . (2001). Cancer Res., 61, 1299–1304.
Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, Wong LC and Ngan HY . (2001). Cancer Res., 61, 5998–6001.
Máximo V, Soares P, Lima J, Cameselle-Teijeiro J and Sobrinho-Simões M . (2002). Am. J. Pathol., 160, 1857–1865.
Mazzaferri EL . (1993). N. Engl. J. Med., 328, 553–559.
Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, Pandit S, Spencer M, Rabitti C, Fazio VM and Sidransky D . (2001). Cancer Res., 61, 7623–7626.
Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW and Vogelstein B . (1998). Nat. Genet., 20, 291–293.
Rieder MJ, Taylor SL, Tobe VO and Nickerson DA . (1998). Nucleic Acids Res., 26, 967–973.
Schmutzler C and Koehrle J . (2000). Eur. J. Endocrinol., 143, 15–24.
Segev DL, Umbricht C and Zeiger MA . (2003). Surg. Oncol., 12, 69–90.
Setterfield K, Williams AJ, Donald J, Thorburn DR, Kirby DM, Trounce I and Christodoulou J . (2002). Mitochondrion, 1, 437–445.
Simonnet H, Alazard N, Pfeiffer K, Gallou C, Beroud C, Demont J, Bouvier R, Schagger H and Godinot C . (2002). Carcinogenesis, 23, 759–768.
Singh KK . (2004). Ann. N. Y. Acad. Sci., 1019, 260–264.
Stefaneanu L and Tasca C . (1979). Endocrinologie, 17, 233–239.
Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama T, Kuma K and Amino N . (2000). Br. J. Cancer, 83, 1495–1502.
Wallace DC . (1994). Proc. Natl. Acad. Sci. USA, 91, 8739–8746.
Wallace DC . (1999). Science, 283, 1482–1488.
Williams AJ, Coakley JC and Christodoulou J . (1999). J. Child Neurol., 14, 518–523.
Yeh JJ, Lunetta KL, van Orsouw NJ, Moore Jr FD, Mutter GL, Vijg J, Dahia PL and Eng C . (2000). Oncogene, 19, 2060–2066.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abu-Amero, K., Alzahrani, A., Zou, M. et al. High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene 24, 1455–1460 (2005). https://doi.org/10.1038/sj.onc.1208292
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208292
Keywords
This article is cited by
-
Mitochondrial DNA variants in colorectal carcinogenesis: Drivers or passengers?
Journal of Cancer Research and Clinical Oncology (2017)
-
Interaction of Age at Diagnosis with Transcriptional Profiling in Papillary Thyroid Cancer
World Journal of Surgery (2016)
-
Mitochondrial variants in MT-CO2 and D-loop instability are involved in MUTYH-associated polyposis
Journal of Molecular Medicine (2015)
-
High mitochondria content is associated with prostate cancer disease progression
Molecular Cancer (2013)
-
Impaired Mitochondrial Metabolism and Mammary Carcinogenesis
Journal of Mammary Gland Biology and Neoplasia (2013)